Zai Lab, Ltd.
NASDAQ:
HK:
ZLAB
9688
Zai Lab, Ltd. is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.
Zai Lab has secured partnerships with leading global biopharma companies, generating a broad and late-stage pipeline of innovative drug candidates. Based on an extensive track record of execution and delivering results, Zai Lab has earned the reputation as a trusted partner of choice for global biopharmaceutical companies seeking to not only access the Chinese market but also find a long-term strategic partner for global clinical development. Through these partnerships, Zai Lab has built the strongest late-stage oncology portfolio with global first-in-class and/or best-in-class profile, among innovative Chinese biotech companies. Zai Lab is further supplementing our pipeline with an in-house discovery effort aiming to produce 1-2 global INDs per year.
Zai Lab is rapidly expanding into a fully integrated biopharmaceutical company, discovering, developing, manufacturing, and commercializing innovative medicines. To that end, it has built its internal R&D center to advance the discovery pipeline, a strong clinical development and operations team, and its own manufacturing facilities in China. Zai Lab has also established a highly specialized commercial team to support marketing of its innovative products in China. Zai Lab believes this integrated approach will provide sustainable competitive advantages.
Zai Lab was successfully listed on the Nasdaq Stock Market in September 2017 and completed secondary listing on Hong Kong Stock Exchange in September 2020. Zai Lab significantly expanded with several offices across China and U.S. and opened its U.S. headquarters in San Francisco in December 2018. As of September 2020, Zai Lab has a global team of over 900 employees.
Key Facts
Auditor
Public Listing
Domicile
HQ/Management
Location of Key Operations
IR Contact
Deloitte Touche Tohmatsu CPA LLP
IPO (September 20, 2017)
Cayman Islands
Shanghai, China
Shanghai, Beijing, Guangzhou, Suzhou, HK, Taiwan, Cambridge, San Francisco
Billy Cho, Internal
86-137-6151-2501
Analyst Coverage
Credit Suisse, Citi, Haitong, Guggenheim, Bank of America/Merril Lynch, Jefferies, CICC, JPM, BOCI, LEERINK, Macquirie, China Renaissance, Goldman Sachs
Latest News
September 24, 2021: Zai Lab Holds Virtual Research and Development Day | Zai Lab Limited (zailaboratory.com)
September 16, 2021: Zai Lab Expands U.S. Operations to Join the Cambridge Biotechnology Community | Zai Lab Limited (zailaboratory.com)
September 14, 2021: Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab (FPA144) in China | Zai Lab Limited (zailaboratory.com)
September 9, 2021: FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer | Zai Lab Limited (zailaboratory.com)
September 9, 2021: Zai Lab to Host Virtual Research and Development Day on September 22, 2021 | Zai Lab Limited (zailaboratory.com)
September 2, 2021: QINLOCK® (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) | Zai Lab Limited (zailaboratory.com)
August 24, 2021: Zai Lab Announces Upcoming Presentations in September Investor Conferences | Zai Lab Limited (zailaboratory.com)
June 18, 2021: Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer | Zai Lab Limited (zailaboratory.com)
May 25, 2021: Zai Lab Announces Upcoming Presentations in June Investor Conferences | Zai Lab Limited (zailaboratory.com)
May 18, 2021: Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials | Zai Lab Limited (zailaboratory.com)
May 10, 2021: Zai Lab Announces First Quarter 2021 Financial Results | Zai Lab Limited (zailaboratory.com)
April 26, 2021: Zai Lab to Announce First Quarter 2021 Financial Results on May 10, 2021 | Zai Lab Limited (zailaboratory.com)
April 22, 2021: OVERSEAS REGULATORY ANNOUNCEMENT
April 20, 2021: Zai Lab Announces Pricing of Public Offering of American Depositary Shares and Ordinary Shares
April 19, 2021: Zai Lab Announces Proposed Public Offering of American Depositary Shares
April 13, 2021: Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
April 9, 2021: Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates
March 31, 2021: China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
March 2, 2021: argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis
March 1, 2021: Zai Lab Announces Financial Results for Second-half and Full-year 2020
February 19, 2021: Zai Lab to Announce Full-Year 2020 Financial Results on March 1, 2021
January 28, 2021: Zai Lab Announces Upcoming Presentations in February Investor Conferences
January 11, 2021: Turning Point and Zai Lab Broaden Collaboration
January 6, 2021: argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China